Full-length MAVS, a mitochondrial antiviral-signaling protein, inhibits hepatitis E virus replication, requiring JAK-STAT signaling

Arch Virol. 2022 May;167(5):1293-1300. doi: 10.1007/s00705-022-05415-9. Epub 2022 Mar 24.

Abstract

Hepatitis E virus (HEV) infection is the leading cause of acute hepatitis worldwide. The mitochondrial antiviral signaling protein (MAVS)-mediated interferon (IFN) response plays a pivotal role in hepatic antiviral immunity. However, little is known about the effect of overexpression of MAVS on HEV infection. Full-length MAVS (FL-MAVS) is the main form of MAVS that increases the production of IFNs. Here, we studied the effect of FL-MAVS on HEV infection. We found that overexpression of FL-MAVS profoundly inhibited HEV replication. Furthermore, we showed that the anti-HEV effect of FL-MAVS is largely dependent on JAK-STAT signaling activation.

MeSH terms

  • Antiviral Agents / pharmacology
  • Hepatitis E virus*
  • Hepatitis E*
  • Humans
  • Immunity, Innate
  • Interferons / pharmacology
  • Virus Replication

Substances

  • Antiviral Agents
  • Interferons